Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview.
The incidence of neuroendocrine tumours of the gastroenteropancreatic system seems to have increased during the past decade. New diagnostic and therapeutic procedures have aroused the interest of physicians, though most see very few cases of such diseases. A group of members of the Nordic Neuroendocrine Tumour Group decided to compile some guidelines to facilitate the diagnosis and treatment of patients with these tumours. Part I of these guidelines discusses the principles of histopathology, biochemical and radiological diagnosis as well as therapeutic options.
Oberg
Kjell
K
Department of Endocrine Oncology, University Hospital, Uppsala, Sweden. kjell.oberg@medsci.uu.se
Astrup
Lone
L
Eriksson
Barbro
B
Falkmer
Sture E
SE
Falkmer
Ursula G
UG
Gustafsen
Jens
J
Haglund
Caj
C
Knigge
Ulrich
U
Vatn
Morten H
MH
Välimäki
Matti
M
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D018358:Neuroendocrine Tumors / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D013953:Thymus Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy
D000970:Antineoplastic Agents